PT-141 + Melanotan II

Source-reported examples · not treatment recommendations

Amount

PT-141: 0.5–1.75 mg per occasion; melanotan II: 0.25–1 mg in loading examples

Frequency

PT-141 as needed, at most once in 24 hours and eight times monthly; melanotan II daily initially

Cycle / observation period

Melanotan II loading: 4–8 weeks, then two or three times weekly

Route / research model

Subcutaneous

Product labeling for bremelanotide does not establish safety of pairing it with melanotan II. This source stack is not an approved combination.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Separate vials: 10 mg + 10 mg. Each ingredient needs its own material total and formulation instructions. These are not premixed products.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.

• Bremelanotide's phase 3 trials evaluated desire and related distress in premenopausal women with hypoactive sexual desire disorder. An older Melanotan II experiment measured erectile responses in a small group of men. These are different populations and endpoints. ^{[1] [2]}
• Two randomized phase 3 trials found improvements in desire and distress measures compared with placebo over 24 weeks. They did not administer a PT-141/Melanotan II stack. ^[1]
• A placebo-controlled crossover experiment studied ten men with erectile dysfunction without a known organic cause. Melanotan II produced erectile responses, with nausea and other transient effects reported more often than after placebo. The study did not include PT-141. ^[2]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Bremelanotide trials
2. Melanotan II experiment
3. FDARegulatory / product information · Listed in reference bibliography.
4. NCBI Bookshelf (LiverTox)Further reading · Listed in reference bibliography.
5. PMCFurther reading · Listed in reference bibliography.
6. Mayo ClinicGeneral guidance · Listed in reference bibliography.
7. PubMedFurther reading · Listed in reference bibliography.
8. RxListFurther reading · Listed in reference bibliography.
9. NCBI Bookshelf (WHO)Further reading · Listed in reference bibliography.
10. HealthlineFurther reading · Listed in reference bibliography.
11. CDCGeneral guidance · Listed in reference bibliography.
12. PMCFurther reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.